|
|
Volumn 23, Issue 28, 2005, Pages 7240-7241
|
|
Alemtuzumab until minimal residual disease for chronic lymphocytic leukemia: Is it a new standard? [12]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALEMTUZUMAB;
FLUDARABINE;
ANTINEOPLASTIC AGENT;
CANCER ANTIBODY;
MONOCLONAL ANTIBODY;
CANCER CHEMOTHERAPY;
CANCER MORTALITY;
CANCER RELAPSE;
CANCER SURVIVAL;
CHRONIC LYMPHATIC LEUKEMIA;
CLINICAL FEATURE;
COST BENEFIT ANALYSIS;
HUMAN;
INFECTION;
LABORATORY TEST;
LETTER;
MEDICAL EDUCATION;
MEDICAL INFORMATION;
MINIMAL RESIDUAL DISEASE;
PATIENT CARE;
PRIORITY JOURNAL;
STANDARDIZATION;
TREATMENT OUTCOME;
TREATMENT RESPONSE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
DRUG ADMINISTRATION;
NOTE;
RANDOMIZED CONTROLLED TRIAL;
SALVAGE THERAPY;
ANTIBODIES, MONOCLONAL;
ANTIBODIES, NEOPLASM;
ANTINEOPLASTIC AGENTS;
DRUG ADMINISTRATION SCHEDULE;
HUMANS;
LEUKEMIA, LYMPHOCYTIC, CHRONIC;
NEOPLASM, RESIDUAL;
RANDOMIZED CONTROLLED TRIALS;
SALVAGE THERAPY;
|
|
EID: 27244459756
PISSN: 0732183X
EISSN: None
Source Type: Journal
DOI: 10.1200/JCO.2005.02.5981 Document Type: Letter |
|
Times cited : (2)
|
|
References (3)
|
